New combo therapy aims to wipe out lung cancer before surgery
NCT ID NCT07050056
First seen Jan 11, 2026 · Last updated May 17, 2026 · Updated 21 times
Summary
This study tests whether combining an immunotherapy drug (tislelizumab) with chest radiation before surgery can improve outcomes for people with early-stage lung cancer (NSCLC). About 20 participants will receive the combination, then have surgery to remove the tumor. The main goal is to see how many patients have no cancer cells left in the removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangsu Northern People Hospital
RECRUITINGYangzhou, Jiangsu, 225001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.